SCHEMBL4570568

SCHEMBL4570568

O=C(O)c1ccc([18F])cc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.85
BAD Q92934 1/20 0.85
TSHR P16473 3/20 0.71
TP53 P04637 1/20 0.71
MITF O75030 1/20 0.65
CES2 O00748 2/20 0.65
CES1 P23141 2/20 0.65
SRD5A2 P31213 2/20 0.60
CA1 P00915 4/20 0.59
CA2 P00918 4/20 0.59
NR4A2 P43354 1/20 0.59
CA12 O43570 1/20 0.57
CA3 P07451 1/20 0.57
TYR P14679 1/20 0.57
DRD1 P21728 1/20 0.57
CA4 P22748 1/20 0.57
CA6 P23280 1/20 0.57
CA5A P35218 1/20 0.57
CA7 P43166 1/20 0.57
CA9 Q16790 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27498 1.00 BCL2L1 (0.85) BCL2L1BADTSHRTP53MITF
SCHEMBL18670950 1.00 BCL2L1 (0.85) BCL2L1BADTSHRTP53MITF
SCHEMBL11452380 0.97 BCL2L1 (0.81) BCL2L1BADTSHRTP53MITF
Methane SCHEMBL6203577 0.97 BCL2L1 (0.81) BCL2L1BADTSHRTP53MITF
SCHEMBL17332097 0.97 BCL2L1 (0.81) BCL2L1BADTSHRTP53MITF
SCHEMBL17332135 0.97 BCL2L1 (0.81) BCL2L1BADTSHRTP53MITF
Fluoride SCHEMBL10732554 0.97 BCL2L1 (0.81) BCL2L1BADTSHRTP53MITF
Ammonia Solution, Strong SCHEMBL4465466 0.97 BCL2L1 (0.81) BCL2L1BADTSHRTP53MITF
SCHEMBL22734857 0.97 BCL2L1 (0.81) BCL2L1BADTSHRTP53MITF
SCHEMBL10607654 0.97 BCL2L1 (0.81) BCL2L1BADTSHRTP53MITF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279225-A1 COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-08-22 US disclosed
US-12023391-B2 Alpha(v)beta(6) integrin-binding peptides and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-07-02 US disclosed
US-20240101601-A1 BI-TERMINAL PEGYLATED INTEGRIN-BINDING PEPTIDES AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-03-28 US disclosed
CN-110662759-B Tumor targeting peptide variants 癌症研究技术有限公司 2024-03-08 CN disclosed
EP-4319755-A1 COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY Board of Regents, The University of Texas System (US) 2024-02-14 EP disclosed
US-20230183317-A1 METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-15 US disclosed
EP-4146268-A2 METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS The Regents of the University of California (US) 2023-03-15 EP disclosed
US-11591369-B2 Alpha(v)beta(6) integrin-binding peptides and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-02-28 US disclosed
US-11485758-B2 Bi-terminal pegylated integrin-binding peptides and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-11-01 US disclosed
WO-2022216979-A1 COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-10-13 WO disclosed
US-20110144344-A1 FLUORIDATION OF IODONIUM SALTS GE HEALTHCARE LIMITED (GB) 2011-06-16 US disclosed
US-7935852-B2 Fluoridation method GE HEALTHCARE LIMITED (GB) 2011-05-03 US disclosed
US-7919579-B2 Imaging and therapeutic targeting of prostate and bladder tissues THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2011-04-05 US disclosed
US-20100322854-A1 POSITRON EMISSION TOMOGRAPHY IMAGING METHOD PURDUE RESEARCH FOUNDATION (US) 2010-12-23 US disclosed
US-20100111838-A1 BRAIN-LOCALIZING POLYPEPTIDES COMPRISING A MULTIVALENT BINDING MOIETY AND IMPROVED METABOLIC STABILITY PROTEUS SCIENCES CO., LTD (JP) 2010-05-06 US disclosed
US-7642373-B2 Forming for example [18F]-dopamine or [18F]-uracil via reaction of iodonium salt precursor, where use of free radical scavenger improves yield of aryl fluoride GE HEALTHCARE LIMITED (GB) 2010-01-05 US disclosed
US-20090123381-A1 IMAGING AND THERAPEUTIC TARGETING OF PROSTATE AND BLADDER TISSUES US ARMY, SECRETARY OF THE ARMY 2009-05-14 US disclosed
US-20080248485-A1 Radiolabeled 3-[3- (Benzoyl-Amido) Benzyloxy] Aspartic Acid Derivative and Method of Producing the Same SUNTORY HOLDINGS LIMITED (JP) 2008-10-09 US disclosed
US-20070276231-A1 Positron Emission Tomography Imaging Method PURDUE RESEARCH FOUNDATION 2007-11-29 US disclosed
US-20070092441-A1 Fluoridation method GE HEALTHCARE LIMITED (GB) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070092441-A1 Fluoridation method FLNB, FLNA, ARFGEF1 BCL2L1 4436/4885BAD 4427/4885TSHR 242/4885
US-20240279225-A1 COMPOUNDS AND METHODS FOR THERANOSTIC TARGETING OF PARP ACTIVITY PARP8, PARP1, PARP3 BCL2L1 2083/4885BAD 34/4885TSHR 1586/4885
US-20110144344-A1 FLUORIDATION OF IODONIUM SALTS ARF5, IPO5, SAMHD1 BCL2L1 3873/4885BAD 1288/4885TSHR 42/4885
US-20230183317-A1 METHODS OF DETECTING AND TREATING LUNG DAMAGE IN RESPIRATORY-RELATED VIRAL INFECTIONS ACE2, ACE, MAVS BCL2L1 1721/4885BAD 4549/4885TSHR 3168/4885
US-20080248485-A1 Radiolabeled 3-[3- (Benzoyl-Amido) Benzyloxy] Aspartic Acid Derivative and Method of Producing the Same SLC1A1, SLC1A5, SLC1A3 BCL2L1 4778/4885BAD 4004/4885TSHR 515/4885
US-20090123381-A1 IMAGING AND THERAPEUTIC TARGETING OF PROSTATE AND BLADDER TISSUES ADM2, DAB2IP, ARG2 BCL2L1 1940/4885BAD 319/4885TSHR 2683/4885
US-20100111838-A1 BRAIN-LOCALIZING POLYPEPTIDES COMPRISING A MULTIVALENT BINDING MOIETY AND IMPROVED METABOLIC STABILITY FABP7, PYGB, DCX BCL2L1 3670/4885BAD 4768/4885TSHR 2718/4885
US-20100322854-A1 POSITRON EMISSION TOMOGRAPHY IMAGING METHOD VDR, FOLR2, SLC46A1 BCL2L1 3588/4885BAD 3994/4885TSHR 287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.